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Platelet activating factor is a lipid mediator of inflammation, and in recent decades, it has emerged as an
important factor in tumor outcomes. Platelet activating factor acts by specific binding to its receptor, which is
present in both tumor cells and cells that infiltrate tumors. Pro-tumorigenic effects of platelet activating factor
receptor in tumors includes promotion of tumor cell proliferation, production of survival signals, migration
of vascular cells and formation of new vessels and stimulation of dendritic cells and macrophages suppressor
phenotype. In experimental models, blocking of platelet activating factor receptor reduced tumor growth and
increased animal survival. During chemotherapy and radiotherapy, tumor cells that survive treatment undergo
accelerated proliferation, a phenomenon known as tumor cell repopulation. Work from our group and others
showed that these treatments induce overproduction of platelet activating factor-like molecules and increase
expression of its receptor in tumor cells. In this scenario, antagonists of platelet activating factor markedly
reduced tumor repopulation. Here, we note that combining chemo- and radiotherapy with platelet activating
factor antagonists could be a promising strategy for cancer treatment.
KEYWORDS: Platelet-activating factor (PAF); PAF receptor (PAFR); PAFR antagonists; tumor repopulation;
radiotherapy; Chemotherapy.
’ INTRODUCTION
Platelet-activating factor (PAF) was first described in the
early 1970s by Benveniste et al. (1) as a soluble factor released
by leukocytes from allergic patients upon stimulation with
the allergen. Structural characterization of the PAF molecule
was performed a few years later through the synthesis of
compounds with similar physicochemical properties (2).
Since these reports, studies have focused on the involvement
of PAF in diverse conditions, including the role of PAF in
tumor growth, which indicated the important role for this
lipid mediator in tumor progression and carcinogenesis (3,4).
PAF production relies on inflammatory stimuli or stress,
such as that induced by radiotherapy and chemotherapy
(5-10). However, under physiologic conditions, a small and
continuous amount of PAF is generated from cell membrane
phospholipids by de novo synthesis, which is responsible
for the functional regulation of plasma membranes (11,12).
During inflammation, large amounts of PAF are generated,
which occurs through the remodeling pathway, where alkyl-
acyl-glycerophosphocholines (GPC) are converted to PAF via
the concerted action of phospholipase A2 and PAF-acetyl-
transferases (LPCATs). In addition to the PAF generated by
enzymatic processes, a wide range of oxidized phospholipids
that bind to the PAF receptor (PAFR) are generated by oxi-
dative stress (13,14). Because these phospholipids can activate
downstream signaling cascades similar to native PAF, we will
use the designation PAFR agonists for all these lipids.
The receptor that binds PAF is a GPCR (G-protein coupled
receptor), cloned by Sugimoto et al. (15), and its activation
induces different effects depending on the cell type. PAFR
was initially described in macrophages, polymorphonuclear
leukocytes, and endothelial cells, among others (2-4). This
receptor is also expressed in some tumor cells, and PAFR
agonists are generated in the tumor microenvironment,
where they exert tumor-promoting effects that are dependent
on the direct effect on tumor cells or cells from the tumor
microenvironment.
In this review, we will first discuss the effects of PAF in
tumor cells and then the PAF effects on cells from the tumor
microenvironment, such as macrophages and endothelial
cells. Finally, the effect of PAFR antagonists on cancer treat-
ment and in tumor cell repopulation after radio- and chemo-
therapy will be addressed.
’ PAFR AND TUMOR CELLS
The expression of PAFR is elevated in several human tumor
lineages [e.g., Kaposi’s sarcoma cells (16), the endometrialDOI: 10.6061/clinics/2018/e792s
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cancer cell line HEC-1A (17), epidermoid carcinoma (A431
cells) (18), the stomach cancer cell line JR-St (19), and N1E-115
neuroblastoma cells (20)]. High amounts of PAFR transcripts
1 and 2 were found in human hepatocellular carcinoma (21)
and gastric adenocarcinoma (22). In tumor cells, PAFR activa-
tion through G-proteins and tyrosine kinases is transduced to
downstream pathways, including NFkB, MAPKs, AKT, PI3
kinase and Src (3,23). Together, these PAFR-activated path-
ways play a central role in oncogenic processes by inducing
tumor cell proliferation. PAF has been reported to promote
non-small cell lung cancer (NSCLC) progression and metas-
tasis by initiating a forward feedback loop between PAFR and
STAT3 (24). PAFR activation also inhibits PTEN activity, lead-
ing to phosphorylation of the PI3K and ERK pathways that
are critical signals for survival, proliferation and differentiation
of tumor cells (25). The role of PAF in tumor cell survival,
proliferation and migration was also shown in ovarian cancer.
Aponte et al. (26) found increased levels of PAFR in serous
ovarian tumors compared to mucinous and benign tumors.
The authors showed that in serous ovarian cancer cells, PAF
promotes cell proliferation and, at the molecular level, PAFR
activation was accompanied by phosphorylation of EGFR, Src,
FAK and paxillin. A few years later, EGF binding to the EGF
receptor was shown to transactivate PAFR, leading to cPLA2
activation and PAF production in ovarian cancer cells (27). In
another study, the same authors (28) verified that both the
PAFR and EGFR signaling pathways promote tumor cell
survival and migration in this tumor type and that the com-
bined targeting of both receptors significantly reduced tumor
growth and progression in nude mice. In primary oral squam-
ous cell carcinoma (OSCC), the enzyme responsible for PAF
synthesis, LPCAT1, is overexpressed compared to that in
normal tissue, and its silencing decreased tumor cell prolifera-
tion and invasiveness (29), indicating that the PAF/PAFR
axis is responsible for sustained prosurvival and proliferative
signaling in malignant cells.
PAF also contributes to the malignant development of
esophageal squamous cell carcinoma by stimulating PI3K/
AKT activation (30). Blockade of the PAFR pathway inhibits
tumor growth of breast cancer (25), prostate cancer (31), and
Kaposi’s sarcoma (32). These effects were associated with the
inhibition of tumor angiogenesis (33). Bussolati and collea-
gues demonstrated that breast cancer cells (MCF7, T-47D,
MDA-MB231) express PAFR and produce PAF in response to
in vitro stimulation with VEGF, bFGF, HGF, TNFa and
thrombin (34), indicating that signals produced in the tumor
microenvironment can induce activation of the PAFR path-
way in tumor cells. Furthermore, PAF can activate cancer cells,
macrophages and endothelial cells to amplify PAF production
and PAFR expression on their membranes in autocrine, endo-
crine, paracrine and juxtracrine interactions (35).
’ PAFR AND THE TUMOR MICROENVIRONMENT
In solid tumors, neoplastic cells grow in the stroma, which
is primarily composed of neoformed vessels, connective
tissue (endothelial cells, fibroblasts and extracellular matrix)
and several cell types recruited from the bloodstream, con-
stituting the tumor inflammatory infiltrate (mainly macro-
phages and lymphocytes) (36). The inflammatory infiltrate
can provide signals that inhibit or stimulate tumor growth
(37). Previous studies from our group have linked the PAF/
PAFR axis with suppression of tumor immunity. We found
that two types of murine tumors, B16F10 melanoma and
TC-1 carcinoma, showed significantly less growth in mice
genetically deficient for PAFR (PAFRKO) than in wild type
(WT) mice. This change occurred in parallel with the increa-
sed frequency of neutrophils and CD4+/CD8+ lymphocyte
infiltration in the tumors implanted in PAFRKO, suggesting
that PAFR may be involved in the recruitment of these cells
into the tumor stroma (38). Macrophages undergo functional
and phenotypic changes in response to signals from the tumor
microenvironment. The role of macrophages in neoplasias is
complex because macrophages can be reprogrammed towards
anti- or protumoral phenotypes (39). M1 phenotype or "classi-
cally activated" macrophages have antitumor activity, and M2
macrophages have protumor effects (40). Moreover, when we
analyzed the macrophages infiltrated in the tumors on day 15,
the PAFKO mice had a higher frequency of M1-like macro-
phages (CD11c+; high iNOS; low arginase; low IL10) than WT
mice, whereas those from WT mice presented the M2 pheno-
type marker (CD206+). Thus, in the absence of PAFR, the tumor
infiltrating macrophages acquire an activated phenotype, which
is associated with the reduced tumor growth observed in PAF
KO animals (38), suggesting that PAFR activation reprograms
macrophages towards the M2 phenotype in experimental
tumors.
The PAF/PAFR axis can also suppress the immune response
by inducing tolerogenic dendritic cells (41) and prolifera-
tion of myeloid-derived suppressor cells (42). In these cells,
PAFR-mediated suppression involves IL10 and prostaglan-
din production (43). PAFR-dependent immunosuppression
was suggested to occur via activation of regulatory T cells
(Tregs) (44-46).
PAFR signaling can also promote modifications in the
tumor microenvironment by inducing angiogenesis through
activation of matrix remodeling metalloproteases (MMPs)
and stimulation of vascular endothelial growth factor (VEGF)
production via NFkB activation (47-50). In vivo, a PAF recep-
tor antagonist inhibited metastasis of human melanoma
cells implanted in nude mice (44). PAF also stimulated CREB-
dependent expression and activation of MMP-2 and vascular
endothelial cell invasion and migration in melanoma (51).
Through activation of the IL-6/STAT3 axis, PAFR induced
epithelial-mesenchymal transition in NSCLC cells (24). In
addition, PAF has been suggested to affect tumor cell
(colon carcinoma and melanoma) adhesiveness to endo-
thelial cells (52).
These results indicate that PAFR signaling may have direct
and indirect effects in promoting cancer progression and
growth and that interfering with PAFR pathways may con-
trol tumor growth.
’ PAFR AND TUMOR REPOPULATION AFTER
CHEMO- AND RADIOTHERAPY
Based on the prosurvival and proliferative effects of PAF
in tumor cells described here, it is likely that the signaling
pathways evoked by PAFR might protect tumor cells dur-
ing chemo- and radiotherapy. Although PAF was shown to
enhance cell death induced by chemotherapy in an epider-
mal carcinoma model transduced with PAFR (7), the oppo-
site effect has been reported by others. In 2006, Heon Seo
et al. (53) observed that PAF led to an increase in the pro-
tein levels of the antiapoptotic proteins Bcl-2 and Bcl-xL
in B16F10 melanoma cells and that costimulation of tumor
cells with PAF and the chemotherapeutic drug etoposide
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protected melanoma cells from etoposide-induced cell death
in an NFkB-dependent manner.
Several years later, studies from Onuchic et al. (54) showed
that in PAFR-expressing human melanoma cells (SKMel37),
cisplatin treatment increased PAFR expression in tumor cells.
Treatment with exogenous PAF protected SKMel37 cells from
cisplatin-induced cell death. Moreover, systemic treatment
with a combination of cisplatin and the PAF-R antagonist
WEB2086 substantially attenuated the growth of SKMel37
tumor xenografts in nude mice (54), suggesting that this
signaling cascade might impair chemotherapeutic efficacy in
melanoma. This effect was clearly demonstrated by Sahu
et al. (55) in B16F10 melanoma-bearing mice treated with
stable PAF (cPAF). Treatment of animals with cPAF caused
a significant increase in tumor growth compared to that of
the control group (vehicle only). In fact, cPAF abrogated the
inhibitory effect of etoposide on tumor growth, highlighting
the prosurvival role of PAF in some cancers.
In an ovarian cancer model, the same chemotherapeutic
agent, cisplatin, led to an increase in PAFR mRNA and pro-
tein levels, which was mediated by NFkB and HIF-1a.
Silencing of PAFR with siRNA or with a PAFR antagonist
increased cisplatin-induced cell death in human ovarian
carcinoma cells, indicating that PAF/PAFR might be invol-
ved in tumor cell survival after genotoxic stress. Using a
SKOV-3-luciferase xenograft model, the authors also showed
that the combined treatment with cisplatin and a PAFR anta-
gonist (ginkgolide B) inhibited tumor progression (56),
reinforcing the hypothesis that the PAF/PAFR axis is invol-
ved in tumor survival and that its blockade impairs tumor
progression.
However, it has been demonstrated in melanoma that
chemotherapy can generate PAFR agonists, which might reduce
chemotherapeutic efficacy in this tumor type. The chemother-
apeutic agents etoposide, dacarbazine, and cisplatin generate
PAF-like molecules in a time- and dose-dependent manner
in B16F10 cells. Furthermore, in a model of dual injection of
B16F10 cells in WT mice, intratumoral treatment with melpha-
lan or etoposide in one tumor augmented the growth of
untreated tumors in a PAFR-dependent manner (57).
Following chemo- and radiotherapy, stressed and dying
cancer cells release a variety of substances, including reactive
oxygen as well as nitrogen species along with cytokines, such
as IL-6, IL-8, and TNF-a, which can activate PAFR agonist
production in the tumor microenvironment (14,58,59). This
tumoral tissue response to genotoxic therapies represents an
indirect pathway to tumor survival through PAFR activation.
Under these conditions, surviving tumor cells undergo cell
proliferation, a phenomenon known as tumor cell repopula-
tion. In a recent Opinion article, Ichim and Tait (2016) (60)
discussed the intrinsic mechanisms that could explain the
unwanted effects of therapies based on cell death. They
noted an early observation made by Revesz in 1956 (61) that
mixing viable tumor cells with dying cells increases tumor
growth. Since then, the molecular mechanisms behind this
phenomenon have been investigated, and in 2011, Huang
et al. (62) showed that in tumor cells undergoing apoptosis
after radiotherapy, activated caspase3 activates cPLA2, leading
to PGE2 synthesis and tumor repopulation.
Several groups have demonstrated that the so-called cancer
stem cells (CSCs) are responsible for tumor repopulation.
Evidence from preclinical studies demonstrated that during
chemotherapy, there is an increase in the frequency of a
subpopulation of quiescent or CSCs that re-enter the cell
cycle, contributing to tumor repopulation (63-65). The activa-
tion of these slow cycling cells is caused by the release of
different factors from dying cells, such as PGE2. An elegant
study by Kurtova et al. (66) showed that blockade of PGE2
abrogates tumor repopulation in response to chemotherapy
in bladder urothelial carcinoma xenografts. PGE2 release by
tumor cells in response to gemcitabine and cisplatin recrui-
ted CSCs to proliferate and repopulate the damaged tissue
as observed in normal wound healing.
Interestingly, in 2012, we demonstrated that PAF is at least
partially responsible for this mitogenic effect of dying cells.
In this study, we observed that the injection of a subtumori-
genic dose of murine melanoma cells admixed with apop-
totic cells promoted tumor engraftment and growth, and this
effect was dependent on PAFR activation (67). In addition,
we also found that increased PGE2 secretion by irradiated
carcinoma cells and PAFR antagonists prevented PGE2 pro-
duction and COX2 expression (68). Although both PAF and
PGE2 induce cell proliferation and survival, PGE2 produc-
tion was dependent on PAF in our studies. This finding can
be explained by the fact that the PAFR pathway is often
associated with arachidonic acid release (12), which can be
converted to prostaglandins through specific enzymes.
In fact, the COX2/PGE2 axis is involved in resistance and
the stemness phenotype in many malignancies (69). Based on
the fact that the CSC phenotype is dynamic., i.e., a single
tumor cell can acquire stem cell properties under certain
circumstances, we speculate that the stem cell-enhancing
activity of PGE2 might be downstream of PAF. However, it is
unclear whether PAF can directly induce the stemness phe-
notype or CSC maintenance in response to genotoxic treat-
ment, contributing to tumor repopulation and treatment failure.
In addition, stressed and dying cancer cells can also release
pro-oxidative stressors that can act directly on GPC to pro-
duce oxidized GPC (ox-GPC), which is a potent PAFR ligand
(7,70-73). The production of these ‘‘PAF-like’’ molecules is
not under the controlled enzymatic process for PAF produc-
tion. Similar to native PAF, these ox-GPCs can increase the
proliferation of remaining tumor cells (9,10), contributing to
tumor repopulation.
Recently, our group reported data that support the concept
that the presence of PAFR ligands in the tumor microenvir-
onment is a possible mechanism underlying tumor repopu-
lation following chemo- and radiotherapy. Working with
human and mouse cancer-derived cell lines, we first showed
that tumor cells produce PAFR ligands after undergoing
gamma irradiation. The irradiated cells co-cultured with live
tumor cells exerted a feeder effect that significantly increased
tumor cell proliferation, and this effect was markedly
reduced by PAFR antagonists added to the co-cultures. In
addition, when PAFR antagonists were added before irradia-
tion, we found a significant decrease in tumor cell viability,
suggesting that PAFR ligands protect tumor cells from death
induced by radiotherapy (68). A similar effect was observed
in experiments designed to simulate the repopulation pheno-
menon. Live TC-1 carcinoma cells were injected subcuta-
neously into mice together with irradiated TC-1 cells. These
tumors grew significantly larger than those that were not
mixed with irradiated cells. This effect was prevented in mice
that were treated with a PAFR antagonist. Further experi-
ments using a human oral carcinoma cell line that does not
express PAFR (KBM) and the same cell line transfected with
PAFR (KBP) confirmed these findings. PAFR+ and PAFR–
tumor cells admixed with irradiated tumor cells were injected
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subcutaneously in RAGKO mice, and tumor growth was
monitored for 30 days. PAFR+ tumors became significantly
larger and more vascularized than PAFR- tumors. Repopula-
tion in PAFR+ tumors was accompanied by an increase in
protumoral macrophage (CD206+) infiltration (9). These
results suggest that during radiotherapy, tumor cells that
survive treatment will undergo accelerated growth, which
is dependent on PAFR activation in tumor cells as well as
tumor macrophages that acquire an activated phenotype.
In prostate cancer, PAFR was overexpressed in response to
irradiation, and the PAFR antagonist ginkgolide B reduced
cell viability. The radiosensitizing effect of this antagonist
was observed in xenograft tumors, and this effect was shown
to be mediated by the interaction between PAFR and beclin-
1, leading to inactivation of autophagy (8).
Based on these studies, we propose that the PAF/PAFR
axis may constitute an important route for acquired resis-
tance after chemo- and radiotherapy in a direct or indirect
manner, as highlighted previously (74). The combined use of
PAFR antagonists with radio- or chemotherapeutic agents
may be a promising strategy against cancer, increasing the
radio- and chemotherapeutic effectiveness.
Treatments based on cell death trigger homeostatic mecha-
nisms within tissues that favor the survival of surrounding
cells. Tumor cell repopulation following chemo- and radio-
therapy is the major drawback of these treatments. We have
discussed here the mechanisms of treatment failure focusing
on the PAF/PAFR axis. During these therapies, cell stress
and oxidative processes generate a wide range of oxidized
phospholipids that bind to PAFR. Our group has shown that
blocking PAFR with selective antagonists was very effective
in reducing tumor cell repopulation following chemo- and
radiotherapy. Thus, PAFR antagonists could improve the
efficacy of radiotherapy through inhibition of tumor repo-
pulation. The association of radiotherapy with PAFR anta-
gonists could be a novel and efficient therapeutic alternative
in cancer treatment.
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